Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

2012/05/06 by Peter Richmond, Peter C Richmond, Helen Marshall +20 · 131 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Adverse effect #Bacterial Infections and Vaccines #Biology #Immune system #Immunization #Immunogenicity #Immunology #Internal medicine #Medicine #Meningococcal vaccine #Neisseria meningitidis #Placebo #Pneumonia and Respiratory Infections #Reactogenicity #Tolerability #Vaccination #vaccines and immunoinformatics approaches

paper · open access · doi:10.1016/s1473-3099(12)70087-7

published in The Lancet Infectious Diseases 12(8), 597-607 (Elsevier BV)

openalex publication_date 2012/05/06 · crossref created 2012/05/06 · crossref issued 2012/08/01 · crossref published 2012/08/01 · crossref published-print 2012/08/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/04/01 · openalex updated_date 2026/07/22

Citations

• Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
• Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

Cited by

• Helen Marshall (vaccinologist) [wikipedia]